<mediadc-video-embed data-state="{"cms.site.owner":{"_ref":"00000161-3486-d333-a9e9-76c6fbf30000","_type":"00000161-3461-dd66-ab67-fd6b93390000"},"cms.content.publishDate":1654619633097,"cms.content.publishUser":{"_ref":"00000162-b63e-dd00-a56b-b67e42560001","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"cms.content.updateDate":1654619633097,"cms.content.updateUser":{"_ref":"00000162-b63e-dd00-a56b-b67e42560001","_type":"00000161-3461-dd66-ab67-fd6b933a0007"},"rawHtml":"
var _bp = _bp||[]; _bp.push({ "div": "Brid_54619363", "obj": {"id":"27789","width":"16","height":"9","video":"1027703"} }); ","_id":"00000181-3a69-d421-ada5-7e7d5ecd0000","_type":"2f5a8339-a89a-3738-9cd2-3ddf0c8da574"}”>Video EmbedThe Food and Drug Administration is set to discuss authorization of the Novavax COVID-19 vaccine, a shot that earned massive government investment in the early throes of the pandemic but hit several manufacturing barriers to regulatory approval.
